Comparative Safety of Empirical Antibiotic Classes in Newly Hospitalized COVID-19 Patients
Kalynn Park, Sohyeon Park, Jung Yoon Choi, Chaeyoon Kim, Jeongha Yun, Jiyeon Bae, Ji Yun Bae, Kang Il Jun, Jeong Han Kim, Chung-Jong Kim, Hee Jung Choi, Sandy Jeong Rhie
IF 4.8 (2025)
Pharmaceuticals
: Empirical fluoroquinolone use at COVID-19 admission may be associated with greater risks of critical care interventions and in-hospital mortality compared to those of 3GCs. These findings highlight the need for careful patient selection and clinical judgment when initiating empirical antibiotic therapy for viral respiratory infections such as COVID-19.
